Investor Relations

Press Releases

Advaxis to Present at the Jefferies 2015 Global Healthcare Conference

Read More

Advaxis Appoints Fred J. Frullo Vice President, Regulatory Affairs

Read More

Advaxis and Sorrento Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies

Read More

Advaxis Appoints Thomas W. Hare Vice President, Clinical Operations

Read More

Advaxis Announces Closing Public Offering of Common Stock With Gross Proceeds Totaling $53.2 Million

Read More

Advaxis Prices $53 Million Public Offering of Common Stock

Read More

Advaxis Announces Proposed Public Offering of Common Stock

Read More

Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property Portfolio With Two USPTO Patents Addressing ADXS-PSA and ADXS-HER2

Read More

Advaxis Presents Lm-LLO Cancer Immunotherapy Data at the 2015 American Association for Cancer Research Meeting

Read More

Advaxis Included Among "25 Top Immunotherapy Companies" in Newly Launched Loncar Cancer Immunotherapy Index (LCINDX)

Read More